Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 10/20 | 0.59 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.57 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 2/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
| ▸ | PGR | P06401 | 5/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7185339 | 1.00 | TNKS (0.59) | TNKSTNKS2PARP2OPRM1PARP1 | |
| SCHEMBL8242664 | 0.93 | TNKS (0.64) | TNKSTNKS2PARP2OPRM1PARP1 | |
| SCHEMBL20334018 | 0.88 | TNKS (0.59) | TNKSTNKS2PARP2OPRM1PARP1 | |
| SCHEMBL7178536 | 0.88 | TNKS (0.59) | TNKSTNKS2PARP2OPRM1PARP1 | |
| SCHEMBL15289117 | 0.87 | TNKS (0.59) | TNKSTNKS2PARP2OPRM1PARP1 | |
| SCHEMBL16456327 | 0.87 | TNKS (0.64) | TNKSTNKS2PARP2OPRM1PARP1 | |
| SCHEMBL16456031 | 0.87 | TNKS (0.64) | TNKSTNKS2PARP2OPRM1PARP1 | |
| SCHEMBL16445244 | 0.87 | TNKS (0.59) | TNKSTNKS2PARP2OPRM1PARP1 | |
| SCHEMBL7181965 | 0.87 | SIRT2 (0.60) | TNKSTNKS2PARP2OPRM1PARP1 | |
| SCHEMBL7190982 | 0.87 | SIRT2 (0.60) | TNKSTNKS2PARP2OPRM1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6582351-B1 | Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-24 | — | — | US | disclosed |